Stockscreener 앱 받기
1.40
3.70%
0.05
시간 외 거래:
1.40
전일 마감가:
$1.35
열려 있는:
$1.37
하루 거래량:
376.63K
Relative Volume:
2.95
시가총액:
$51.20M
수익:
-
순이익/손실:
$-9.16M
주가수익비율:
-2.4561
EPS:
-0.57
순현금흐름:
$-8.75M
1주 성능:
+17.65%
1개월 성능:
+44.36%
6개월 성능:
+10.24%
1년 성능:
+19.66%
1일 변동 폭
$1.31
$1.40
1주일 범위
$1.20
$1.40
52주 변동 폭
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
RNXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.40 | 43.52M | 0 | -9.16M | -8.75M | -0.57 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
New U.S. Patent Issued to RenovoRx for Drug Therapy Platform - Medical Product Outsourcing
RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment - simplywall.st
Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright - Defense World
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates - MSN
RenovoRx (NASDAQ:RNXT) Receives “Buy” Rating from HC Wainwright - Defense World
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook - TipRanks
RenovoRx (RNXT): HC Wainwright Reiterates Buy Rating with $3.00 Target | RNXT Stock News - GuruFocus
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript - MSN
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating - TipRanks
RenovoRx Earnings Call: Positive Outlook Amid Growth - TipRanks
RenovoRx Inc (RNXT) Q1 2025 Earnings: EPS of -$0.08 Beats Estima - GuruFocus
RenovoRx earnings beat, revenue fell short of estimates - Investing.com Australia
Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations By Investing.com - Investing.com Nigeria
RenovoRx Reports Promising Q1 2025 Financial Results - TipRanks
Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations - Investing.com
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com India
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace
RenovoRx Q1 2025 Earnings Call Transcript - MarketBeat
RenovoRx reports Q1 EPS (8c), consensus (8c) - TipRanks
RenovoRx (RNXT) Reports Strong Q1 Revenue Surpassing Expectations | RNXT Stock News - GuruFocus
RenovoRx Reports Strong Q1 2025 Financial Results - TipRanks
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - BioSpace
RenovoRx Expands RenovoCath Production to Meet an Increasing Demand - Zenopa
Renaissance Technologies LLC Makes New Investment in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World
RenovoRx Ramps Up U.S. Production of RenovoCath Devices - Medical Product Outsourcing
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire
RenovoRx (RNXT) Projected to Post Earnings on Friday - Defense World
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - BioSpace
CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer - Curetoday
Ascendiant Capital Markets Forecasts Strong Price Appreciation for RenovoRx (NASDAQ:RNXT) Stock - The AM Reporter
RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer T - GuruFocus
RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer Treatment | RNXT Stock News - GuruFocus
Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial - Business Wire
RenovoRx (NASDAQ:RNXT) Price Target Raised to $11.00 at Ascendiant Capital Markets - Defense World
RenovoRx Reports Initial Revenue and Clinical Trial Progress - MSN
RenovoRx CMO Makes Bold Stock Purchase! - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock By Investing.com - Investing.com Canada
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock By Investing.com - Investing.com South Africa
Jersey Shore debuts N.J.’s first TAMP cancer therapy - ROI-NJ
RenovoRx ramps up production of FDA-cleared RenovoCath By Investing.com - Investing.com India
New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment | Newswise - Newswise
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock - Investing.com Australia
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock By Investing.com - Investing.com Canada
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - BioSpace
RenovoRx ramps up production of FDA-cleared RenovoCath - Investing.com
Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community - marketscreener.com
Medical Device Maker RenovoRx Eyes $400M Market With Surging RenovoCath Demand - Stock Titan
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):